|
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|
Nov 2020
|
Annals of Oncology: Official Journal of the European Society for Medical Oncology
|
myelodysplastic syndromes (MDS)
|
|
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes
|
Oct 2020
|
Annals of internal medicine
|
myelodysplastic syndromes (MDS)
|
|
Evolving therapies for lower-risk myelodysplastic syndromes
|
Apr 2020
|
Annals of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry
|
May 2020
|
Annals of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series
|
Jan 2021
|
Annals of Hematology
|
aplastic anemia
|
|
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
|
Oct 2019
|
Annals of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry
|
Jul 2020
|
Annals of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Recent Developments in Drug Therapy for Aplastic Anemia
|
Sep 2014
|
Ann Pharmacother
|
aplastic anemia
|
|
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
|
Sep 2014
|
Ann Oncol
|
myelodysplastic syndromes (MDS)
|
|
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
|
Oct 2015
|
Ann Oncol
|
myelodysplastic syndromes (MDS)
|
